. . . .Speaking at the BioFinance and BioInnovate Europe meeting in London at the end of last week, Margaret Beer, head of licensing and external research in Europe for Merck Sharp & Dohme, noted that the newly-expanded company, fresh from its acquistion of Schering-Plough, is still very much in the market for other partnerships. She said the merger means that “Merck is now a bigger beast to feed”. . . .
As for technologies, they do not have to be new, she said, they just need to be “faster, better and cheaper than what we already have”. Dr Beer concluded by noting that “we rarely come across an opportunity that’s unique” but partnerships are vital; last year 63% of Merck’s 2009 sales were attributable to alliance products and patents. . . .
So, read this as sheer size is not always an advantage -- especially when Wall Street expects a high, and steady rate of percentage growth -- on an already gargantuan base of revenue and EPS. And that steady growth is increasingly hard to come by, when one's pipeline is slowly, but surely, drying up.